Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Sorrento Therpt (SRNE)

Sorrento Therpt (SRNE)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 614,535
  • Shares Outstanding, K 388,946
  • Annual Sales, $ 52,900 K
  • Annual Income, $ -428,330 K
  • 60-Month Beta 2.43
  • Price/Sales 11.10
  • Price/Cash Flow N/A
  • Price/Book 2.60
Trade SRNE with:

Options Overview Details

View History
  • Implied Volatility 160.04% ( -12.08%)
  • Historical Volatility 91.44%
  • IV Percentile 98%
  • IV Rank 40.71%
  • IV High 295.04% on 04/06/22
  • IV Low 67.36% on 09/23/21
  • Put/Call Vol Ratio 0.29
  • Today's Volume 3,627
  • Volume Avg (30-Day) 2,272
  • Put/Call OI Ratio 0.09
  • Today's Open Interest 235,999
  • Open Int (30-Day) 219,859

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate -0.25
  • Number of Estimates 2
  • High Estimate -0.22
  • Low Estimate -0.28
  • Prior Year 0.01
  • Growth Rate Est. (year over year) -2,600.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.1500 +38.26%
on 05/12/22
1.8400 -13.59%
on 04/21/22
-0.2000 (-11.17%)
since 04/20/22
3-Month
1.1500 +38.26%
on 05/12/22
2.8950 -45.08%
on 02/22/22
-1.2600 (-44.21%)
since 02/18/22
52-Week
1.1500 +38.26%
on 05/12/22
11.0700 -85.64%
on 07/01/21
-5.6200 (-77.95%)
since 05/20/21

Most Recent Stories

More News
Scilex, a Sorrento Company, Announces Initiation of a Phase 2 Study to Evaluate the Safety and Efficacy of SP-103 in Subjects with Acute Low Back Pain

Dosing of the first subject in a Phase 2, randomized, double-blind, placebo-controlled, parallel group, multicenter study to evaluate the safety and...

SRNE : 1.5900 (+0.63%)
Sorrento Therapeutics, Inc. Appoints Former Roche Executive Tammy Reilly to the Board of Directors

SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Sorrento Therapeutics, Inc (Nasdaq: SRNE, “Sorrento”), a commercial and clinical-stage biopharmaceutical...

SRNE : 1.5900 (+0.63%)
Sorrento’s License Partner, Lee’s Pharm, Announces Full Enrollment of 498 Patients in a Phase III Trial of Socazolimab (Anti-PD-L1 Antibody) for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer (ES-SCLC)

Socazolimab (anti-PD-L1 monoclonal antibody) was discovered by Sorrento from its fully human antibody G-MABTM library and licensed by China Oncology Focus...

SRNE : 1.5900 (+0.63%)
Kamada (KMDA) Reports Q1 Loss, Lags Revenue Estimates

Kamada (KMDA) delivered earnings and revenue surprises of -233.33% and 13.37%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

KMDA : 4.63 (-0.96%)
SRNE : 1.5900 (+0.63%)
Albireo Pharma (ALBO) Reports Q1 Loss, Lags Revenue Estimates

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -8.42% and 12.62%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ALBO : 22.32 (+0.68%)
SRNE : 1.5900 (+0.63%)
Scilex Holding Company, a Sorrento Company, and Vickers Vantage Corp. I announced today the filing of a Registration Statement on Form S-4 with the Securities and Exchange Commission relating to the previously announced proposed business combination

PALO ALTO, Calif. and NEW YORK, May 16, 2022 (GLOBE NEWSWIRE) -- Scilex Holding Company (“Scilex”), a Sorrento Company (nearly 100% or over 99.9%...

SRNE : 1.5900 (+0.63%)
Aravive (ARAV) Reports Q1 Loss, Tops Revenue Estimates

Aravive (ARAV) delivered earnings and revenue surprises of -16.98% and 2.54%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

ARAV : 1.0700 (-0.93%)
SRNE : 1.5900 (+0.63%)
Scilex, a Sorrento Company, Announces Pivotal Phase 3 SP-102 (SEMDEXA™) Data Presentation At The American Society Of Interventional Pain (ASIPP) 2022 Annual Meeting

SP-102 (SEMDEXATM) is the first non-opioid novel injectable corticosteroid gel formulation product in development for the treatment of lumbar radicular...

SRNE : 1.5900 (+0.63%)
Levena Biopharma, A Sorrento Company, Announces Positive Clinical Data for Its Out-Licensed A166 Product Candidate, A Third-Generation Anti-HER2-ADC, In Treating Heavily Pretreated HER2-Positive Breast Cancer Patients

A166 is a third-generation antibody drug conjugate (ADC) against HER2-positive breast cancer with Levena Biopharma’s proprietary tubulin inhibitor Duo-5...

SRNE : 1.5900 (+0.63%)
Why Sorrento Therapeutics Stock Shot 7% Higher Today

The company delivers some encouraging news about a COVID drug.

SRNE : 1.5900 (+0.63%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Sorrento Therapeutics, Inc. is a biopharmaceutical company. It is focused primarily on the acquisition, discovery, development and commercialization of proprietary oncology therapeutics. The Company researches human therapeutic antibodies for the treatment of cancer, inflammation, metabolic disease and...

See More

Key Turning Points

3rd Resistance Point 1.7900
2nd Resistance Point 1.7100
1st Resistance Point 1.6500
Last Price 1.5900
1st Support Level 1.5100
2nd Support Level 1.4300
3rd Support Level 1.3700

See More

52-Week High 11.0700
Fibonacci 61.8% 7.2806
Fibonacci 50% 6.1100
Fibonacci 38.2% 4.9394
Last Price 1.5900
52-Week Low 1.1500

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar